Markets:

Overview

News

Currencies

International

Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

13.91 -0.16 (-1.10%)

Streaming Delayed Price Updated: 12:23 PM EDT, Jun 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

20 21 Next >

Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023 ↗

March 14, 2023

Via Benzinga

Analyst Ratings for Intellia Therapeutics ↗

March 14, 2023

Via Benzinga

2 Cathie Wood Stocks That Have Tripled Since the 2020 Market Crash ↗

March 09, 2023

Are these stocks still good buys today?

Via The Motley Fool

7 Cathie Wood Stocks for Your March Buy List ↗

March 07, 2023

These top Cathie Wood stocks are just now attempting to pivot higher after a miserable outing for much of 2022.

Via InvestorPlace

Why Is Intellia Therapeutics (NTLA) Stock Up 10% Today? ↗

March 02, 2023

Huge opportunities also meets unignorable risks

Via InvestorPlace

Why Intellia Therapeutics Stock Jumped This Week ↗

March 02, 2023

Intellia Therapeutics landed a historic regulatory nod from the FDA.

Via The Motley Fool

Intellia Therapeutics Earnings Perspective: Return On Capital Employed ↗

February 28, 2023

Via Benzinga

Stock Market Rally Rebounds Despite Rising Yields; Salesforce, Tesla In Focus: Weekly Review ↗

March 03, 2023

Many leaders flashed buy signals as the indexes rebounded from support.

Via Investor's Business Daily

Why Is Intellia Therapeutics Stock Trading Higher Today? ↗

March 02, 2023

Intellia Therapeutics (NASDAQ: NTLA) shares are trading higher on Thursday after the company announced that the FDA cleared its Investigational New Drug application for NTLA-2002 for the treatment of...

Via Benzinga

Intellia Therapeutics Stock Surges On A First-Ever In CRISPR Gene Editing ↗

March 02, 2023

The FDA made a bold move in the CRISPR gene-editing realm.

Via Investor's Business Daily

3 More Mid-Cap Biotechs The Street Sees Doubling

February 22, 2023

According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk.

Via MarketBeat

Top CRISPR Stocks ↗

February 11, 2023

CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses.

Via Talk Markets

Expert Ratings for Intellia Therapeutics ↗

January 24, 2023

Via Benzinga

The Latest Analyst Ratings for Intellia Therapeutics ↗

January 04, 2023

Via Benzinga

Earnings Scheduled For February 23, 2023 ↗

February 23, 2023

Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter.

Via Benzinga

Better Buy: Beam Therapeutics or Intellia Therapeutics? ↗

February 22, 2023

The two clinical-stage gene-editing companies have good long-term prospects.

Via The Motley Fool

3 Deeply Undervalued Stocks That Could Double Your Money ↗

February 15, 2023

These cutting-edge biotech stocks hold tremendous upside potential.

Via The Motley Fool

3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall Street ↗

February 07, 2023

These stocks are risky. But they just might deliver huge gains if analysts are right.

Via The Motley Fool

3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129% ↗

February 06, 2023

Cathie Wood is bullish about these stocks. And so are Wall Street analysts.

Via The Motley Fool

When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader? ↗

February 05, 2023

A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?

Via Talk Markets

Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock ↗

February 01, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 1, 2023 ↗

February 01, 2023

Via Benzinga

7 CRISPR Stocks With the Best Long-Term Potential ↗

January 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

Via InvestorPlace

3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later ↗

January 25, 2023

Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time.

Via InvestorPlace

3 Gene Editing Stocks With the Best Long-Term Potential ↗

January 25, 2023

These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space

Via InvestorPlace

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

January 24, 2023

The growth-focused money manager is making moves.

Via The Motley Fool

Stocks That Hit 52-Week Lows On Friday ↗

January 20, 2023

Friday saw 23 companies set new 52-week lows.

Via Benzinga

2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years ↗

January 07, 2023

Both are hoping to use the latest gene editing technology to make the lucrative therapies of tomorrow.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023 ↗

January 24, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2023 ↗

January 19, 2023

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.